Effects of cardio-pulmonary bypass on vancomycin plasma concentration decay.
The objective of the study was to investigate possible changes in vancomycin serum levels induced by cardio-pulmonary bypass (CPB). Ten cardiac patients (seven males, three females, aged between 56 and 81), who underwent cardiac surgery requiring CPB, took part in the study. Vancomycin (15 mg kg-1) was intravenously infused over 60 min before anaesthesia and blood samples were taken at appropriate times after drug administration (0, 0.5, 1, 6, 8 h), after starting CPB (0, 5, 30 and 60 min) and after aortic unclamping (0, 5, 30, 60, 120 min). Drug serum concentrations were determined by means of a fluorescence polarization immunoassay. The area under the concentration-time curve (AUC) measured during CPB were compared with the AUC extrapolated in the same interval by fitting a two-compartment pharmacokinetic model to drug concentrations obtained before and after CPB. Five minutes after starting CPB vancomycin serum levels decreased, on average, by 40.9% and remained steadily lower than the expected values over the next 60 min. In the same interval, the measured AUC was 31.7% lower than the expected AUC. In no instance did serum levels fall below the MIC for most common pathogens (1-2 mg l-1). At aortic unclamping serum levels slightly rebounded but tended to remain lower than the expected concentrations over the next 120 min. In conclusion, during CPB vancomycin serum levels invariably decreased but, at the dose employed (15 mg kg-1), remained in a potentially effective range for antimicrobial prophylaxis.
Miglioli
P A
PA
Department of Pharmacology, University of Padova, Largo Meneghetti 2, Padova, Italy.
Merlo
F
F
Grabocka
E
E
Padrini
R
R
D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000097:blood* / Q000493:pharmacokinetics*; D019540:Area Under Curve; D002315:Cardiopulmonary Bypass; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014640:Vancomycin / Q000097:blood* / Q000493:pharmacokinetics* / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D014640:Vancomycin